Translation and Implementation of the Dutch VVAS Score in Clinical Practice

NCT06017466 | Unknown DMC

• 1 other identifier: 22493VVAS
• Study Type: interventional
• Target: 10
• Locations: 0 countries
• Sites: N/A

Brief Summary

The aim of this study is to translate and introduce a cross-cultural adaptation of The Visual Vertigo Analogue Scale (VVAS). E. Dannenbaum et al developed the VVAS in order to diagnose visual vertigo (VV). VV is dizziness caused by visual stimuli such as scrolling through a computer screen or walking through crowds of people or supermarket aisles.

Conditions

Vertigo

Keywords

Vertigo; Epidemiology; Visually Induced Dizziness; Chronic Vertigo

Outcome Measures

Primary Outcomes (1)

• vertigo symptoms assessed by the visual analogue scale

  Unit of measurement: score from 1 to 10 measurement tool: VVAS questionnaire

  1 year

Study Arms (1)

Chronic Vertigo

EXPERIMENTAL

Chronic vertigo patients can be divided into three groups. The first pathway is episodic vertigo (caused by e.g. migraine, Ménière's disease, benign paroxysmal positional vertigo (BPPV)) progressively leading to chronic dizziness. The second pathway is initiated by a single attack of vertigo (e.g. neuritis vestibularis) with some initial recovery but later on residual symptoms. The third pathway is the presence of chronic, slowly progressive, continuous, or unchanging symptoms (e.g. bilateral vestibular failure, CNS disorders). All patient with chronic vertigo (see above) will included.

Diagnostic Test: Visual Vertigo Analogue Scale (VVAS)

Interventions

Visual Vertigo Analogue Scale (VVAS) DIAGNOSTIC_TEST

The Visual Vertigo Analogue Scale (VVAS) was developed by E. Dannenbaum et al in 2011 to diagnose visual vertigo. It is a nine-item analogue scale in which the subjects can rated the intensity of their symptoms. The symptoms can be categorized as None (0), Mild (0.1-40), Moderate (40.01-70) or Severe (70.01-100). The VVAS is already available in English and French but a Dutch version does not yet exist.

Chronic Vertigo

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All patient with chronic vertigo (\>3 years) will included
• Interpretation of the VVAS is be possible
• year

You may not qualify if:

• Unable to read Dutch
• Single episode of vertigo
• \> 75 year
• Minors
• When no interpretation of the VVAS is possible (e.g. too young, dementia)

Sponsors & Collaborators

• Universitair Ziekenhuis Brussel: lead

MeSH Terms

Conditions

Vertigo

Condition Hierarchy (Ancestors)

Vestibular Diseases; Labyrinth Diseases; Ear Diseases; Otorhinolaryngologic Diseases; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Marie Reynders, MD

CONTACT

+32477261213; marie.reynders@uzbrussel.be

Vedat Topsakal, Prof, MD

CONTACT

1926881; vedat.topsakal@uzbrussel.be

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DEVICE FEASIBILITY
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This will be a prospective interventional study with the Dutch VVAS questionnaire as interventional product.

Study Record Dates

• First Submitted: March 15, 2023
• First Posted: August 30, 2023
• Study Start: October 1, 2023
• Primary Completion: January 1, 2024
• Study Completion: March 1, 2024
• Last Updated: August 30, 2023

Record last verified: 2022-12